ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01169298
Recruitment Status : Completed
First Posted : July 26, 2010
Last Update Posted : October 31, 2016
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation